Nothing Special   »   [go: up one dir, main page]

AR025609A1 - Formulaciones lipidas solidas - Google Patents

Formulaciones lipidas solidas

Info

Publication number
AR025609A1
AR025609A1 ARP000104722A ARP000104722A AR025609A1 AR 025609 A1 AR025609 A1 AR 025609A1 AR P000104722 A ARP000104722 A AR P000104722A AR P000104722 A ARP000104722 A AR P000104722A AR 025609 A1 AR025609 A1 AR 025609A1
Authority
AR
Argentina
Prior art keywords
solid lipid
lipid formulations
fatty acid
acid ester
depoliol
Prior art date
Application number
ARP000104722A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR025609(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR025609A1 publication Critical patent/AR025609A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

El presente invento se refiere a una composicion farmacéutica que comprende por lo menos un inhibidor de lipasas y por lo menos un éster de ácido graso depolioles, caracterizado porque el éster de ácido graso tiene un punto de fusion por encima de latemperatura corporal y los polioles se eligen del grupoconstituido por azucares, derivados de azucar y sus mezclas.
ARP000104722A 1999-09-13 2000-09-08 Formulaciones lipidas solidas AR025609A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99118179 1999-09-13

Publications (1)

Publication Number Publication Date
AR025609A1 true AR025609A1 (es) 2002-12-04

Family

ID=8238989

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104722A AR025609A1 (es) 1999-09-13 2000-09-08 Formulaciones lipidas solidas

Country Status (36)

Country Link
US (1) US6703369B1 (es)
EP (1) EP1216048B1 (es)
JP (1) JP4217017B2 (es)
KR (1) KR100523879B1 (es)
CN (1) CN1197554C (es)
AR (1) AR025609A1 (es)
AT (1) ATE285783T1 (es)
AU (1) AU769016B2 (es)
BR (1) BRPI0013940B1 (es)
CA (1) CA2383036C (es)
CO (1) CO5210857A1 (es)
CZ (1) CZ301844B6 (es)
DE (1) DE60017156T2 (es)
EG (1) EG24225A (es)
ES (1) ES2233444T3 (es)
GC (1) GC0000259A (es)
HK (1) HK1049798B (es)
HR (1) HRP20020206B1 (es)
HU (1) HU229037B1 (es)
IL (2) IL148570A0 (es)
JO (1) JO2300B1 (es)
MA (1) MA26817A1 (es)
ME (1) MEP90908A (es)
MX (1) MXPA02002662A (es)
MY (1) MY127430A (es)
NO (1) NO328889B1 (es)
NZ (1) NZ517396A (es)
PE (1) PE20010661A1 (es)
PL (1) PL199869B1 (es)
PT (1) PT1216048E (es)
RS (1) RS50373B (es)
RU (1) RU2248218C2 (es)
SI (1) SI1216048T1 (es)
TR (1) TR200200605T2 (es)
WO (1) WO2001019378A2 (es)
ZA (1) ZA200201249B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011091816A1 (en) 2010-02-01 2011-08-04 Laboratorios Bagó S.A. Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
EP1307264B1 (en) * 2000-07-28 2004-10-20 F. Hoffmann-La Roche Ag New pharmaceutical composition
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6730319B2 (en) 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
DE10251963A1 (de) * 2002-11-08 2004-05-19 Lts Lohmann Therapie-Systeme Ag Transmucosale pharmazeutische Darreichungsform
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
EP1599189A4 (en) * 2003-03-04 2009-07-01 Nostrum Pharmaceuticals Inc FORMULATION WITH CONTROLLED RELEASE AND WITH WATER-REPELLENT MATERIAL AS A MEANS FOR DELAYED RELEASE
FI20045076A (fi) * 2004-03-15 2005-09-16 Bioferme Oy Funktionaalinen elintarvike
AU2005297923B2 (en) * 2004-10-25 2010-12-23 Japan Tobacco Inc. Solid medicinal preparation improved in solubility and stability and process for producing the same
KR100669497B1 (ko) * 2005-08-17 2007-01-16 보람제약주식회사 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
CA2626234A1 (en) * 2005-12-22 2007-06-28 Teva Pharmaceutical Industries Ltd. Compressed solid dosage forms with drugs of low solubility and process for making the same
EP1808163A1 (en) * 2005-12-22 2007-07-18 Teva Pharmaceutical Industries Ltd. Compressed solid dosage forms with drugs of low solubility and process for making the same
KR101252635B1 (ko) 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
KR100903504B1 (ko) * 2007-05-18 2009-06-17 강태용 비라칸사스 열매 추출물질을 포함하는 기능식품 및 체중 감소제
EP2076248A2 (en) * 2007-08-17 2009-07-08 Teva Pharmaceutical Industries Ltd. Methods and compositions for controlling the bioavailability of poorly soluble drugs
PL2036575T3 (pl) * 2007-09-12 2011-02-28 Mader S R L Kompozycje farmaceutyczne do stosowania doustnie w leczeniu pacjentów dotkniętych otyłością
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
WO2010042499A1 (en) * 2008-10-06 2010-04-15 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
BRPI0901602B8 (pt) 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
EP2486805A1 (en) * 2011-02-11 2012-08-15 Puratos N.V. An emulsion whippable at room-temperature
MY162951A (en) * 2011-04-14 2017-07-31 J Oil Mills Inc Palm-based and fractionated oil and fat, oil and fat composition and foods mixed with the same
CN102552168B (zh) * 2012-01-31 2013-08-07 杭州华东医药集团生物工程研究所有限公司 一种含有奥利司他的药物组合物及其制备方法
GB2501535A (en) 2012-04-26 2013-10-30 Sony Corp Chrominance Processing in High Efficiency Video Codecs
IN2014DN10548A (es) * 2012-05-31 2015-08-21 Repros Therapeutics Inc
AU2014343899A1 (en) * 2013-10-28 2016-03-17 Nestec S.A. Monoacylglycerols for use in conjunction with a lipase inhibitor and/or diets low in fat and/or calories
CN115105476B (zh) * 2021-03-23 2023-11-14 山东新时代药业有限公司 一种奥利司他冻干口服制剂及其制备工艺

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
FR2710264B1 (fr) * 1993-09-21 1995-12-08 Rocher Yves Biolog Vegetale Utilisation pour le traitement des peaux mixtes d'une quantité efficace de substances actives.
WO1998024607A1 (en) * 1996-12-04 1998-06-11 Pincott James S Process and apparatus for making crumb rubber from scrap tyres
NZ336755A (en) 1997-02-05 2001-06-29 F Use of gastrointestinal lipase inhibitors in particular tetrahydrolipstatin (orlistat)
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
KR20010079636A (ko) * 1998-08-14 2001-08-22 프리돌린 클라우스너, 롤란드 비. 보레르 라이페이즈 저해제 및 키토산을 포함하는 약학 조성물
BR9912980B1 (pt) 1998-08-14 2013-10-22 Composição farmacêutica administrável oralmente, tablete de mascar contendo a mesma e utilização da mesma
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011091816A1 (en) 2010-02-01 2011-08-04 Laboratorios Bagó S.A. Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process

Also Published As

Publication number Publication date
EP1216048A2 (en) 2002-06-26
CN1373659A (zh) 2002-10-09
RU2248218C2 (ru) 2005-03-20
ATE285783T1 (de) 2005-01-15
HK1049798A1 (en) 2003-05-30
MY127430A (en) 2006-11-30
DE60017156T2 (de) 2006-01-05
US6703369B1 (en) 2004-03-09
WO2001019378A3 (en) 2001-05-10
CO5210857A1 (es) 2002-10-30
CZ301844B6 (cs) 2010-07-07
IL148570A (en) 2007-03-08
CA2383036A1 (en) 2001-03-22
PL199869B1 (pl) 2008-11-28
HUP0202762A3 (en) 2005-04-28
WO2001019378A2 (en) 2001-03-22
HRP20020206B1 (en) 2011-02-28
DE60017156D1 (de) 2005-02-03
GC0000259A (en) 2006-11-01
PE20010661A1 (es) 2001-06-25
NO20021205D0 (no) 2002-03-12
CA2383036C (en) 2006-01-10
ZA200201249B (en) 2003-07-30
ME00675B (me) 2011-12-20
AU7517700A (en) 2001-04-17
TR200200605T2 (tr) 2002-08-21
KR100523879B1 (ko) 2005-10-26
HU229037B1 (en) 2013-07-29
MA26817A1 (fr) 2004-12-20
EG24225A (en) 2008-11-10
AU769016B2 (en) 2004-01-15
NO20021205L (no) 2002-03-12
NO328889B1 (no) 2010-06-07
PL356154A1 (en) 2004-06-14
IL148570A0 (en) 2002-09-12
HK1049798B (zh) 2005-08-05
HRP20020206A2 (en) 2004-04-30
RS50373B (sr) 2009-11-10
BR0013940A (pt) 2002-05-14
CN1197554C (zh) 2005-04-20
EP1216048B1 (en) 2004-12-29
YU13602A (sh) 2006-01-16
JO2300B1 (en) 2005-09-12
CZ20021277A3 (cs) 2003-04-16
HUP0202762A2 (hu) 2003-01-28
NZ517396A (en) 2003-10-31
RU2002107450A (ru) 2004-01-10
ES2233444T3 (es) 2005-06-16
KR20020060177A (ko) 2002-07-16
SI1216048T1 (en) 2005-06-30
BRPI0013940B1 (pt) 2016-06-21
JP2003509373A (ja) 2003-03-11
MXPA02002662A (es) 2002-07-30
PT1216048E (pt) 2005-04-29
MEP90908A (en) 2011-12-20
JP4217017B2 (ja) 2009-01-28

Similar Documents

Publication Publication Date Title
AR025609A1 (es) Formulaciones lipidas solidas
ZA200200259B (en) Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents.
HN2000000224A (es) Aminoacidos biciclicos como agentes farmaceuticos
WO2005079853A3 (en) Soft gelatin capsule comprising omega-3 polyunsaturated fatty acid
ATE478129T1 (de) Kerzenwachs auf triacylglycerin-basis
PL346149A1 (en) Amphoteric derivatives of aliphatic polyamines with fatty acids, esters or triglycerides
CO4940469A1 (es) Composicion oral de estabilidad mejorada que comprende un derivado de indolinona y una mezcla de gliceridos o esteres de polietilenglicol
ES2191862T3 (es) Composicion liquida que comprende un inhibidor de la vih proteasa y un acido graso de c12-c18.
HRP20010615B1 (en) Pharmaceutical compositions containing proton pump inhibitors
MXPA05010607A (es) Composiciones de distribucion de farmacos de ester de alfa-hidroxiacido y metodos de uso.
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
HRP20030983B1 (en) Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester
ES2192036T3 (es) Agentes anti-tumorales.
AR016629A1 (es) Una solucion que comprende un azaesteroide farmaceuticamente activo y un ester de acido graso de glicerol o propilen glicol, composiciones farmaceuticasque comprenden la solucion y capsulas de gelatina rellenas con la composicion farmaceutica.
ECSP003653A (es) Formulaciones solidas de lipido
UY26337A1 (es) Formulaciones de lipidos solidos
WO2002049582A3 (de) Kosmetische und dermatologische lichtschutzformulierungen mit einem gehalt an benzotriazolderivaten und oberflächenaktiven zitronensäureestern
AR004489A1 (es) Benzopiranos, su utilizacion para preparar medicamentos, las composiciones farmaceuticas que los contienen, los procedimientos para preparar dichos compuestos y compuestos intermediarios
DK0991741T3 (da) Voksestere, som er beriget med omega-3-umættede fedtsyrer, deres fremstilling og anvendelse
TH58483B (th) สูตรผสมไขมันที่เป็นของแข็ง
AR017652A1 (es) Esferoides que contienen uno o varios principios activos excepto tiagabina, procedimiento para su preparacion, composiciones farmaceuticas que loscontienen y procedimiento para su preparacion
HN1996000075A (es) Nueva variante cristalina del cdch procedimientos para su produccion y preparados farmaceuticos que lo contienen.
HN1996000074A (es) Formulaciones farmaceuticas
DK1216048T3 (da) Faste lipidformuleringer, der omfatter en inhibitor af lipaser og en fedtsyreester af polyoler

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration